{"recordsFiltered":49578,"recordsTotal":49578,"next":null,"previous":"http://staging-fdaaa.ebmdatalab.net/api/trials/?format=json&length=300&ordering=days_late&start=49200","results":[{"registry_id":"NCT04699591","publication_url":"https://clinicaltrials.gov/study/NCT04699591","title":"Compassionate Use of Domperidone for Refractory Gastroparesis","has_exemption":false,"start_date":"2013-04-30","completion_date":"2035-12-31","has_results":false,"results_due":false,"sponsor_name":"Jose Cocjin","sponsor_slug":"jose-cocjin","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT02469662","publication_url":"https://clinicaltrials.gov/study/NCT02469662","title":"Retrospective and Prospective Clinical Outcomes Study of the Zimmer® Nexel™ Total Elbow","has_exemption":false,"start_date":"2015-06-30","completion_date":"2035-12-31","has_results":false,"results_due":false,"sponsor_name":"Zimmer Biomet","sponsor_slug":"zimmer-biomet","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT04042025","publication_url":"https://clinicaltrials.gov/study/NCT04042025","title":"A Long-term Follow-up Study of Patients in the Clinical Trials for Spinal Muscular Atrophy Receiving AVXS-101","has_exemption":false,"start_date":"2020-02-10","completion_date":"2035-12-31","has_results":false,"results_due":false,"sponsor_name":"Novartis Gene Therapies","sponsor_slug":"novartis-gene-therapies","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06697301","publication_url":"https://clinicaltrials.gov/study/NCT06697301","title":"A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants With Advanced Melanoma (TeLuRide-006)","has_exemption":false,"start_date":"2025-05-22","completion_date":"2035-12-31","has_results":false,"results_due":false,"sponsor_name":"Eikon Therapeutics","sponsor_slug":"eikon-therapeutics","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07282834","publication_url":"https://clinicaltrials.gov/study/NCT07282834","title":"Randomized Phase II Trial of Heated Vs. Pressurized/Aerosolized Chemotherapy (HIPEC vs. PIPAC) for Peritoneal Carcinomatosis","has_exemption":false,"start_date":"2026-01-05","completion_date":"2035-12-31","has_results":false,"results_due":false,"sponsor_name":"Patrick Wagner, MD, FACS","sponsor_slug":"patrick-wagner-md-facs","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07186634","publication_url":"https://clinicaltrials.gov/study/NCT07186634","title":"Domain-Specific Appendix: OXYGEN","has_exemption":false,"start_date":"2026-04-06","completion_date":"2035-12-31","has_results":false,"results_due":false,"sponsor_name":"Monash University","sponsor_slug":"monash-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07365319","publication_url":"https://clinicaltrials.gov/study/NCT07365319","title":"A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer (TeLuRide-008).","has_exemption":false,"start_date":"2026-06-15","completion_date":"2035-12-31","has_results":false,"results_due":false,"sponsor_name":"Eikon Therapeutics","sponsor_slug":"eikon-therapeutics","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07447076","publication_url":"https://clinicaltrials.gov/study/NCT07447076","title":"A Platform Study of Novel Therapies for Children, Adolescents and Young Adults With Recurrent/Progressive Atypical Teratoid Rhabdoid Tumor (ATRT)","has_exemption":false,"start_date":"2026-06-17","completion_date":"2035-12-31","has_results":false,"results_due":false,"sponsor_name":"Sabine Mueller, MD, PhD","sponsor_slug":"sabine-mueller-md-phd","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07240649","publication_url":"https://clinicaltrials.gov/study/NCT07240649","title":"Emerging Indications for Hyperbaric Oxygen Treatment","has_exemption":false,"start_date":"2026-08-31","completion_date":"2035-12-31","has_results":false,"results_due":false,"sponsor_name":"Jay C. Buckey Jr.","sponsor_slug":"jay-c-buckey-jr","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04074135","publication_url":"https://clinicaltrials.gov/study/NCT04074135","title":"Evaluation of the Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors","has_exemption":false,"start_date":"2020-06-02","completion_date":"2036-01-30","has_results":false,"results_due":false,"sponsor_name":"National Cancer Institute (NCI)","sponsor_slug":"national-cancer-institute-nci","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07308886","publication_url":"https://clinicaltrials.gov/study/NCT07308886","title":"Phase II Study of Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-response (REGIMEN-KS HIV)","has_exemption":false,"start_date":"2026-04-08","completion_date":"2036-01-31","has_results":false,"results_due":false,"sponsor_name":"National Cancer Institute (NCI)","sponsor_slug":"national-cancer-institute-nci","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT02445222","publication_url":"https://clinicaltrials.gov/study/NCT02445222","title":"Long Term Follow-Up of Patients Exposed to Lentiviral-Based CAR T-Cell Therapy","has_exemption":false,"start_date":"2015-11-02","completion_date":"2036-02-22","has_results":false,"results_due":false,"sponsor_name":"Novartis Pharmaceuticals","sponsor_slug":"novartis-pharmaceuticals","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT06892522","publication_url":"https://clinicaltrials.gov/study/NCT06892522","title":"A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of Etentamig Monotherapy or Etentamig Combinations in Subjects With Multiple Myeloma","has_exemption":false,"start_date":"2025-06-30","completion_date":"2036-02-29","has_results":false,"results_due":false,"sponsor_name":"AbbVie","sponsor_slug":"abbvie","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07677839","publication_url":"https://clinicaltrials.gov/study/NCT07677839","title":"Redefining the Normal: Ultra-High Frequency Ultrasound Characterization of Lymphatic Anatomy in Patients With Breast Cancer","has_exemption":false,"start_date":"2026-06-17","completion_date":"2036-03-01","has_results":false,"results_due":false,"sponsor_name":"University of California, Davis","sponsor_slug":"university-of-california-davis","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05767047","publication_url":"https://clinicaltrials.gov/study/NCT05767047","title":"A Phase 3, Multicenter, Open-label, Long-term Extension Study of Apremilast in Children 2 Years of Age or Older With Oral Ulcers Associated With Behçet's Disease or 5 Years of Age or Older With Juvenile Psoriatic Arthritis","has_exemption":false,"start_date":"2023-03-23","completion_date":"2036-03-17","has_results":false,"results_due":false,"sponsor_name":"Amgen","sponsor_slug":"amgen","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07577414","publication_url":"https://clinicaltrials.gov/study/NCT07577414","title":"Infant Survival and Long-term Outcome Following Fetoscopic Endoluminal Tracheal Occlusion in Severe Left and Right Congenital Diaphragmatic Hernia, A Phase III Trial","has_exemption":false,"start_date":"2026-06-17","completion_date":"2036-04-30","has_results":false,"results_due":false,"sponsor_name":"Dr Erin Perrone","sponsor_slug":"dr-erin-perrone","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT02201992","publication_url":"https://clinicaltrials.gov/study/NCT02201992","title":"A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein","has_exemption":false,"start_date":"2015-03-23","completion_date":"2036-05-01","has_results":false,"results_due":false,"sponsor_name":"ECOG-ACRIN Cancer Research Group","sponsor_slug":"ecog-acrin-cancer-research-group","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT03955445","publication_url":"https://clinicaltrials.gov/study/NCT03955445","title":"An Open-label, Non-randomized Extension Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Iptacopan (LNP023) in C3 Glomerulopathy or Idiopathic Immune-complex-membranoproliferative Glomerulonephritis","has_exemption":false,"start_date":"2019-10-03","completion_date":"2036-05-30","has_results":false,"results_due":false,"sponsor_name":"Novartis Pharmaceuticals","sponsor_slug":"novartis-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06918002","publication_url":"https://clinicaltrials.gov/study/NCT06918002","title":"A Phase 3, Open-label, Controlled, Randomized Study of Newly Diagnosed Multiple Myeloma Treatment, Designed to Evaluate the Efficacy and Safety of the Elranatamab-lenalidomide Combination as a Replacement for Chemotherapy Followed by Autologous Stem Cell Transplant in the Consolidation Phase, and to Compare Elranatamab With Standard of Care in the Maintenance Phase","has_exemption":false,"start_date":"2025-07-09","completion_date":"2036-05-31","has_results":false,"results_due":false,"sponsor_name":"Intergroupe Francophone du Myelome","sponsor_slug":"intergroupe-francophone-du-myelome","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07250477","publication_url":"https://clinicaltrials.gov/study/NCT07250477","title":"Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer","has_exemption":false,"start_date":"2026-01-30","completion_date":"2036-05-31","has_results":false,"results_due":false,"sponsor_name":"University of California, Davis","sponsor_slug":"university-of-california-davis","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07393373","publication_url":"https://clinicaltrials.gov/study/NCT07393373","title":"Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children With Hypochondroplasia: ACCEL OLE","has_exemption":false,"start_date":"2026-04-23","completion_date":"2036-05-31","has_results":false,"results_due":false,"sponsor_name":"QED Therapeutics, a BridgeBio company","sponsor_slug":"qed-therapeutics-a-bridgebio-company","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07659379","publication_url":"https://clinicaltrials.gov/study/NCT07659379","title":"Extension Trial to Study the Long-term Safety and Efficacy in Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in Gotistobart Trials","has_exemption":false,"start_date":"2026-07-01","completion_date":"2036-07-01","has_results":false,"results_due":false,"sponsor_name":"OncoC4, Inc.","sponsor_slug":"oncoc4-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07671768","publication_url":"https://clinicaltrials.gov/study/NCT07671768","title":"ONE SHOT: Single-Fraction Adaptive MR-Guided Radiation Therapy for Metastatic Solid Tumors","has_exemption":false,"start_date":"2026-07-01","completion_date":"2036-07-01","has_results":false,"results_due":false,"sponsor_name":"Jonsson Comprehensive Cancer Center","sponsor_slug":"jonsson-comprehensive-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05441813","publication_url":"https://clinicaltrials.gov/study/NCT05441813","title":"A Randomized, Open-label Study of Coconut Oil Mouth Rinse for Prophylaxis of Severe Oral Mucositis in Pediatric Patients Receiving Myeloablative Conditioning Regimens","has_exemption":false,"start_date":"2023-02-15","completion_date":"2036-07-31","has_results":false,"results_due":false,"sponsor_name":"Wake Forest University Health Sciences","sponsor_slug":"wake-forest-university-health-sciences","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07708961","publication_url":"https://clinicaltrials.gov/study/NCT07708961","title":"Randomized Phase II Trial to Evaluate the Efficacy of WSD0922-FU When Combined With Adjuvant Temozolomide in Patients With EGFR Mutant Glioblastoma","has_exemption":false,"start_date":"2026-08-16","completion_date":"2036-07-31","has_results":false,"results_due":false,"sponsor_name":"Mayo Clinic","sponsor_slug":"mayo-clinic","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06342999","publication_url":"https://clinicaltrials.gov/study/NCT06342999","title":"Evaluation of Outcomes of Fetal Aortic Valvuloplasty for Evolving Hypoplastic Left Heart Syndrome","has_exemption":false,"start_date":"2027-01-01","completion_date":"2036-07-31","has_results":false,"results_due":false,"sponsor_name":"Mauro H. Schenone","sponsor_slug":"mauro-h-schenone","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07654257","publication_url":"https://clinicaltrials.gov/study/NCT07654257","title":"Single FrAction Interstitial BreaSt BracHytherApy (SASHA)","has_exemption":false,"start_date":"2026-09-01","completion_date":"2036-09-30","has_results":false,"results_due":false,"sponsor_name":"Virginia Commonwealth University","sponsor_slug":"virginia-commonwealth-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07667400","publication_url":"https://clinicaltrials.gov/study/NCT07667400","title":"Phase I/II Trial of Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer","has_exemption":false,"start_date":"2026-07-22","completion_date":"2036-10-01","has_results":false,"results_due":false,"sponsor_name":"National Cancer Institute (NCI)","sponsor_slug":"national-cancer-institute-nci","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07420959","publication_url":"https://clinicaltrials.gov/study/NCT07420959","title":"Phase 1/2 Trial of ABBV-383 for Patients With Relapsed Refractory Waldenström Macroglobulinemia","has_exemption":false,"start_date":"2026-10-25","completion_date":"2036-10-25","has_results":false,"results_due":false,"sponsor_name":"Mayo Clinic","sponsor_slug":"mayo-clinic","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03435796","publication_url":"https://clinicaltrials.gov/study/NCT03435796","title":"Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells","has_exemption":false,"start_date":"2018-07-19","completion_date":"2036-11-30","has_results":false,"results_due":false,"sponsor_name":"Celgene","sponsor_slug":"celgene","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06072482","publication_url":"https://clinicaltrials.gov/study/NCT06072482","title":"A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Participants With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis","has_exemption":false,"start_date":"2024-02-07","completion_date":"2036-12-31","has_results":false,"results_due":false,"sponsor_name":"Amgen","sponsor_slug":"amgen","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05669846","publication_url":"https://clinicaltrials.gov/study/NCT05669846","title":"Phase II Feasibility Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC","has_exemption":false,"start_date":"2025-01-08","completion_date":"2036-12-31","has_results":false,"results_due":false,"sponsor_name":"Diwakar Davar","sponsor_slug":"diwakar-davar","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06974279","publication_url":"https://clinicaltrials.gov/study/NCT06974279","title":"Precision Neuromodulation in Post-Stroke Aphasia Using TMS","has_exemption":false,"start_date":"2025-09-01","completion_date":"2036-12-31","has_results":false,"results_due":false,"sponsor_name":"Medical College of Wisconsin","sponsor_slug":"medical-college-of-wisconsin","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06932562","publication_url":"https://clinicaltrials.gov/study/NCT06932562","title":"A Randomized, Open-Label, Controlled Phase 3 Study of Comparing Daratumumab, Lenalidomide and Dexamethasone Induction Followed by Linvoseltamab Versus Continued Daratumumab, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients","has_exemption":false,"start_date":"2025-12-23","completion_date":"2036-12-31","has_results":false,"results_due":false,"sponsor_name":"European Myeloma Network B.V.","sponsor_slug":"european-myeloma-network-bv","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05548972","publication_url":"https://clinicaltrials.gov/study/NCT05548972","title":"Global, Multicenter and Prospective Post-Market Clinical Follow-Up Study of the G7® Dual Mobility Acetabular System With Vivacit-E® or Longevity® Poly Bearing & Instrumentation","has_exemption":false,"start_date":"2023-03-20","completion_date":"2037-01-31","has_results":false,"results_due":false,"sponsor_name":"Zimmer Biomet","sponsor_slug":"zimmer-biomet","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06938399","publication_url":"https://clinicaltrials.gov/study/NCT06938399","title":"Motiva Implants® Post-Approval Study (PAS) Protocol for Motiva SmoothSilk® Round Ergonomix® ('Ergonomix®') and SmoothSilk® Round ('Round') Breast Implants in Subjects Who Are Undergoing Primary Breast Augmentation, Revision Augmentation and Other Aesthetic Procedures","has_exemption":false,"start_date":"2025-05-01","completion_date":"2037-04-01","has_results":false,"results_due":false,"sponsor_name":"Motiva USA LLC","sponsor_slug":"motiva-usa-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03935893","publication_url":"https://clinicaltrials.gov/study/NCT03935893","title":"A Phase 2 Study to Evaluate the Efficacy and Safety of Adoptive Transfer of Autologous Tumor Infiltrating Lymphocytes in Patients With Advanced Solid Cancers","has_exemption":false,"start_date":"2019-12-03","completion_date":"2037-06-30","has_results":false,"results_due":false,"sponsor_name":"Udai Kammula","sponsor_slug":"udai-kammula","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05201781","publication_url":"https://clinicaltrials.gov/study/NCT05201781","title":"Long-term Follow-up Study for Participants Previously Treated With Ciltacabtagene Autoleucel","has_exemption":false,"start_date":"2022-03-09","completion_date":"2037-07-29","has_results":false,"results_due":false,"sponsor_name":"Janssen Research & Development, LLC","sponsor_slug":"janssen-research-development-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06986382","publication_url":"https://clinicaltrials.gov/study/NCT06986382","title":"Phase 1b/2a Trial of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset (EO), Medically Refractory (MR) Crohn Disease (CD)","has_exemption":false,"start_date":"2025-07-31","completion_date":"2037-07-31","has_results":false,"results_due":false,"sponsor_name":"Stanford University","sponsor_slug":"stanford-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05281809","publication_url":"https://clinicaltrials.gov/study/NCT05281809","title":"A Feasibility Study Following a Phase 2a Design to Demonstrate Successful Local Manufacture of Chimeric Antigen Receptor (CAR) T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia","has_exemption":false,"start_date":"2022-04-19","completion_date":"2037-08-05","has_results":false,"results_due":false,"sponsor_name":"John Lister","sponsor_slug":"john-lister","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07214532","publication_url":"https://clinicaltrials.gov/study/NCT07214532","title":"SIgnatera-Guided Initiation of Adjuvant CDK4/6 Inhibitor in Intermediate Risk HR+ HER2- Breast Cancer","has_exemption":false,"start_date":"2026-03-24","completion_date":"2037-11-15","has_results":false,"results_due":false,"sponsor_name":"Natera, Inc.","sponsor_slug":"natera-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06191744","publication_url":"https://clinicaltrials.gov/study/NCT06191744","title":"A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2)","has_exemption":false,"start_date":"2024-02-05","completion_date":"2037-11-30","has_results":false,"results_due":false,"sponsor_name":"Genmab","sponsor_slug":"genmab","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06661720","publication_url":"https://clinicaltrials.gov/study/NCT06661720","title":"Short TeRm Intensified Pembrolizumab (KEytruda) and Tivozanib for High-Risk Renal Cell Carcinoma - STRIKE","has_exemption":false,"start_date":"2025-03-14","completion_date":"2037-11-30","has_results":false,"results_due":false,"sponsor_name":"Alliance for Clinical Trials in Oncology","sponsor_slug":"alliance-for-clinical-trials-in-oncology","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07116473","publication_url":"https://clinicaltrials.gov/study/NCT07116473","title":"A Phase 3, Open-Label, Multicenter, Extension Study of Acoramidis in Patients With Newly Diagnosed Variant Transthyretin Amyloid Cardiomyopathy (ACT-EARLY OLE)","has_exemption":false,"start_date":"2025-11-30","completion_date":"2037-11-30","has_results":false,"results_due":false,"sponsor_name":"Eidos Therapeutics, a BridgeBio company","sponsor_slug":"eidos-therapeutics-a-bridgebio-company","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07637513","publication_url":"https://clinicaltrials.gov/study/NCT07637513","title":"Phase III Trial of Consolidation Tarlatamab + Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer (LS-SCLC)","has_exemption":false,"start_date":"2027-01-31","completion_date":"2037-11-30","has_results":false,"results_due":false,"sponsor_name":"PrECOG, LLC.","sponsor_slug":"precog-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06651281","publication_url":"https://clinicaltrials.gov/study/NCT06651281","title":"A Phase 3 Extension Study to Evaluate the Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis","has_exemption":false,"start_date":"2024-11-25","completion_date":"2037-12-17","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05587244","publication_url":"https://clinicaltrials.gov/study/NCT05587244","title":"Multicenter, Prospective Post-Market Clinical Follow-Up Study of the G7® Freedom Constrained Vivacit-E® Liners","has_exemption":false,"start_date":"2023-05-08","completion_date":"2037-12-31","has_results":false,"results_due":false,"sponsor_name":"Zimmer Biomet","sponsor_slug":"zimmer-biomet","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT01770418","publication_url":"https://clinicaltrials.gov/study/NCT01770418","title":"A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer","has_exemption":false,"start_date":"2013-03-31","completion_date":"2038-01-31","has_results":false,"results_due":false,"sponsor_name":"Proton Collaborative Group","sponsor_slug":"proton-collaborative-group","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT04192591","publication_url":"https://clinicaltrials.gov/study/NCT04192591","title":"A 5-year Superion™ IDS Clinical Outcomes Post-Approval Evaluation (SCOPE)","has_exemption":false,"start_date":"2020-01-30","completion_date":"2038-02-28","has_results":false,"results_due":false,"sponsor_name":"Boston Scientific Corporation","sponsor_slug":"boston-scientific-corporation","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03989947","publication_url":"https://clinicaltrials.gov/study/NCT03989947","title":"A Phase 2 Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children With Achondroplasia","has_exemption":false,"start_date":"2019-06-12","completion_date":"2038-05-31","has_results":false,"results_due":false,"sponsor_name":"BioMarin Pharmaceutical","sponsor_slug":"biomarin-pharmaceutical","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03538899","publication_url":"https://clinicaltrials.gov/study/NCT03538899","title":"Phase I/II Safety and Efficacy Study of Gene Transfer for Artemis-Deficient Severe Combined Immunodeficiency (ART-SCID) in Newly Diagnosed Patients Using Self-Inactivating Lentiviral Vector (AProArt) to Transduce Autologous CD34 Hematopoietic Cells","has_exemption":false,"start_date":"2018-05-31","completion_date":"2038-06-30","has_results":false,"results_due":false,"sponsor_name":"University of California, San Francisco","sponsor_slug":"university-of-california-san-francisco","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05976763","publication_url":"https://clinicaltrials.gov/study/NCT05976763","title":"A Randomized Phase 3 Trial of Continuous vs. Intermittent Maintenance Therapy With Zanubrutinib as Upfront Treatment in Older Patients With Mantle Cell Lymphoma","has_exemption":false,"start_date":"2023-10-20","completion_date":"2038-08-31","has_results":false,"results_due":false,"sponsor_name":"Alliance for Clinical Trials in Oncology","sponsor_slug":"alliance-for-clinical-trials-in-oncology","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT00912041","publication_url":"https://clinicaltrials.gov/study/NCT00912041","title":"BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia","has_exemption":false,"start_date":"2009-05-31","completion_date":"2038-09-30","has_results":false,"results_due":false,"sponsor_name":"Leigh R. Hochberg, MD, PhD.","sponsor_slug":"leigh-r-hochberg-md-phd","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT04081701","publication_url":"https://clinicaltrials.gov/study/NCT04081701","title":"68Ga(Gallium)-DOTATATE Positron Emission Tomography (PET)/MRI in the Diagnosis and Management of Somatostatin Receptor Positive Central Nervous System CNS Tumors.","has_exemption":false,"start_date":"2019-09-04","completion_date":"2038-12-31","has_results":false,"results_due":false,"sponsor_name":"Weill Medical College of Cornell University","sponsor_slug":"weill-medical-college-of-cornell-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05929807","publication_url":"https://clinicaltrials.gov/study/NCT05929807","title":"A Phase 2, Multicenter, Long-Term, Open Label Extension Trial Evaluating Safety, Tolerability, and Efficacy of Subcutaneous Doses of TransCon CNP Administered Once Weekly in Children and Adolescents With Achondroplasia","has_exemption":false,"start_date":"2023-06-21","completion_date":"2039-01-31","has_results":false,"results_due":false,"sponsor_name":"Ascendis Pharma Growth Disorders A/S","sponsor_slug":"ascendis-pharma-growth-disorders-as","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07226388","publication_url":"https://clinicaltrials.gov/study/NCT07226388","title":"Hemiarthroplasty Versus Total Shoulder Arthroplasty for the Treatment of Glenohumeral Osteoarthritis: The Impact of Modern Implant Options","has_exemption":false,"start_date":"2026-02-03","completion_date":"2039-02-28","has_results":false,"results_due":false,"sponsor_name":"Washington University School of Medicine","sponsor_slug":"washington-university-school-of-medicine","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06582745","publication_url":"https://clinicaltrials.gov/study/NCT06582745","title":"Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib","has_exemption":false,"start_date":"2024-06-24","completion_date":"2039-06-30","has_results":false,"results_due":false,"sponsor_name":"Cook Children's Health Care System","sponsor_slug":"cook-childrens-health-care-system","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06498635","publication_url":"https://clinicaltrials.gov/study/NCT06498635","title":"Randomized Phase III Trial INcorporating Pathologic Complete ReSponse in Participants With Early StaGe Non Small Cell Lung Cancer to Optimize ImmunotHerapy in The AdjuvanT Setting (INSIGHT)","has_exemption":false,"start_date":"2025-04-01","completion_date":"2039-07-15","has_results":false,"results_due":false,"sponsor_name":"National Cancer Institute (NCI)","sponsor_slug":"national-cancer-institute-nci","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06652633","publication_url":"https://clinicaltrials.gov/study/NCT06652633","title":"A Long-term Follow-up Study for Patients Treated With Galapagos CAR T-cell Therapies","has_exemption":false,"start_date":"2024-09-09","completion_date":"2039-07-31","has_results":false,"results_due":false,"sponsor_name":"Lakefront Biotherapeutics NV","sponsor_slug":"lakefront-biotherapeutics-nv","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06598371","publication_url":"https://clinicaltrials.gov/study/NCT06598371","title":"A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors","has_exemption":false,"start_date":"2024-11-21","completion_date":"2039-08-01","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04208529","publication_url":"https://clinicaltrials.gov/study/NCT04208529","title":"A Long-term Follow-up Study of Subjects With β-thalassemia or Sickle Cell Disease Treated With Autologous CRISPR-Cas9 Modified Hematopoietic Stem Cells (CTX001)","has_exemption":false,"start_date":"2021-01-20","completion_date":"2039-09-30","has_results":false,"results_due":false,"sponsor_name":"Vertex Pharmaceuticals Incorporated","sponsor_slug":"vertex-pharmaceuticals-incorporated","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07431827","publication_url":"https://clinicaltrials.gov/study/NCT07431827","title":"A Phase 3, Randomized, Double-blind Study of Adjuvant MK-1084 Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) Versus Adjuvant Placebo Plus MK-3475A in Participants With Completely Resected Stage IIA-IIIB (N2), KRAS G12C-mutant Non-small Cell Lung Cancer Following Receipt of Either Neoadjuvant Pembrolizumab Plus Chemotherapy or Adjuvant Chemotherapy (KANDLELIT-013)","has_exemption":false,"start_date":"2026-03-18","completion_date":"2039-10-26","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT02598349","publication_url":"https://clinicaltrials.gov/study/NCT02598349","title":"A Phase II Trial of Escalated Dose Proton Radiotherapy With Elective Nodal Irradiation and Concomitant Chemotherapy for Patients With Unresectable, Borderline Resectable or Medically Inoperable Pancreatic Adenocarcinoma","has_exemption":false,"start_date":"2016-04-30","completion_date":"2039-10-31","has_results":false,"results_due":false,"sponsor_name":"Proton Collaborative Group","sponsor_slug":"proton-collaborative-group","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT06617286","publication_url":"https://clinicaltrials.gov/study/NCT06617286","title":"MAC-CAR: A Phase 1B/II Trial of Myeloablative Conditioning and Autologous Stem Cell Transplantation Followed by Autologous CD30+ CAR T Cells in Children, Adolescents and Young Adults With Poor-Risk Classical Hodgkin Lymphoma (cHL)","has_exemption":false,"start_date":"2026-12-01","completion_date":"2039-12-31","has_results":false,"results_due":false,"sponsor_name":"New York Medical College","sponsor_slug":"new-york-medical-college","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03007589","publication_url":"https://clinicaltrials.gov/study/NCT03007589","title":"Natural Sunlight Protection and Simulated Sunlight Protection Offered by Sunscreens and Fabrics","has_exemption":false,"start_date":"2014-04-30","completion_date":"2040-01-31","has_results":false,"results_due":false,"sponsor_name":"Sun Protection Foundation","sponsor_slug":"sun-protection-foundation","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT05568719","publication_url":"https://clinicaltrials.gov/study/NCT05568719","title":"A PHASE 3, NON-INVESTIGATIONAL PRODUCT, MULTI COUNTRY COHORT STUDY TO DESCRIBE THE LONG-TERM SAFETY AND EFFECTIVENESS OF A PRIOR SINGLE-DOSE TREATMENT WITH INVESTIGATIVE GIROCTOCOGENE FITELPARVOVEC OR FIDANACOGENE ELAPARVOVEC IN PARTICIPANTS WITH HEMOPHILIA A OR HEMOPHILIA B, RESPECTIVELY","has_exemption":false,"start_date":"2022-12-28","completion_date":"2040-02-25","has_results":false,"results_due":false,"sponsor_name":"Pfizer","sponsor_slug":"pfizer","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05849480","publication_url":"https://clinicaltrials.gov/study/NCT05849480","title":"A Phase I/II Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)","has_exemption":false,"start_date":"2024-05-08","completion_date":"2040-06-01","has_results":false,"results_due":false,"sponsor_name":"National Cancer Institute (NCI)","sponsor_slug":"national-cancer-institute-nci","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05620771","publication_url":"https://clinicaltrials.gov/study/NCT05620771","title":"Phase II Study Therasphere® (Yttrium-90) in Combination With Systemic Therapy in Patients With High-risk Hepatocellular Carcinoma","has_exemption":false,"start_date":"2022-11-30","completion_date":"2040-07-01","has_results":false,"results_due":false,"sponsor_name":"Northwestern University","sponsor_slug":"northwestern-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT02689440","publication_url":"https://clinicaltrials.gov/study/NCT02689440","title":"Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Dasatinib and Venetoclax: A Phase II Study","has_exemption":false,"start_date":"2016-02-19","completion_date":"2040-12-31","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT07073014","publication_url":"https://clinicaltrials.gov/study/NCT07073014","title":"A Phase 3, Open-Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of Vosoritide in Children With Hypochondroplasia","has_exemption":false,"start_date":"2025-06-20","completion_date":"2040-12-31","has_results":false,"results_due":false,"sponsor_name":"BioMarin Pharmaceutical","sponsor_slug":"biomarin-pharmaceutical","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT02760849","publication_url":"https://clinicaltrials.gov/study/NCT02760849","title":"WISP (Women Choosing Surgical Prevention)","has_exemption":false,"start_date":"2016-05-02","completion_date":"2041-05-31","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT07095452","publication_url":"https://clinicaltrials.gov/study/NCT07095452","title":"Phase 2/3, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Subjects With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant","has_exemption":false,"start_date":"2026-01-08","completion_date":"2042-01-31","has_results":false,"results_due":false,"sponsor_name":"AbbVie","sponsor_slug":"abbvie","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05962346","publication_url":"https://clinicaltrials.gov/study/NCT05962346","title":"Pilot Trial of Fetoscopic Endoluminal Tracheal Occlusion for Severe Left Congenital Diaphragmatic Hernia","has_exemption":false,"start_date":"2026-12-31","completion_date":"2043-07-31","has_results":false,"results_due":false,"sponsor_name":"Mauro H. Schenone","sponsor_slug":"mauro-h-schenone","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03486873","publication_url":"https://clinicaltrials.gov/study/NCT03486873","title":"A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab","has_exemption":false,"start_date":"2018-08-21","completion_date":"2043-08-04","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06281730","publication_url":"https://clinicaltrials.gov/study/NCT06281730","title":"Use of New Generation Fetoscopes in Pregnancies Affected by Fetal Diseases Amenable to Fetoscopy Therapy","has_exemption":false,"start_date":"2024-03-23","completion_date":"2044-02-29","has_results":false,"results_due":false,"sponsor_name":"Mayo Clinic","sponsor_slug":"mayo-clinic","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06358638","publication_url":"https://clinicaltrials.gov/study/NCT06358638","title":"Sickle Cell Disease Transplant Using a Nonmyeloablative Approach: Adding Daratumumab for Patients With Anti-donor Red Cell AntibodY","has_exemption":false,"start_date":"2024-04-03","completion_date":"2044-09-30","has_results":false,"results_due":false,"sponsor_name":"Children's National Research Institute","sponsor_slug":"childrens-national-research-institute","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT01538056","publication_url":"https://clinicaltrials.gov/study/NCT01538056","title":"Physician Modified Endovascular Grafts for the Treatment of Elective, Symptomatic or Ruptured Juxtarenal Aortic Aneurysm: An Investigator Initiated Study","has_exemption":false,"start_date":"2011-03-31","completion_date":"2045-01-31","has_results":false,"results_due":false,"sponsor_name":"University of Washington","sponsor_slug":"university-of-washington","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT02917460","publication_url":"https://clinicaltrials.gov/study/NCT02917460","title":"Genomic Biorepository: Protocol for the Collection, Storage, Analysis, and Distribution of Biological Samples, Genomic and Clinical Data","has_exemption":false,"start_date":"2016-07-31","completion_date":"2050-12-31","has_results":false,"results_due":false,"sponsor_name":"Rady Pediatric Genomics & Systems Medicine Institute","sponsor_slug":"rady-pediatric-genomics-systems-medicine-institute","status":"ongoing","is_pact":true,"days_late":null}]}